| Drug General Information |
| Drug ID |
D0I7BL
|
| Former ID |
DNC008409
|
| Drug Name |
ARISTEROMYCIN
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Terminated |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C11H15N5O3
|
| Canonical SMILES |
C1C(C(C(C1N2C=NC3=C2N=CN=C3N)O)O)CO
|
| InChI |
1S/C11H15N5O3/c12-10-7-11(14-3-13-10)16(4-15-7)6-1-5(2-17)8(18)9(6)19/h3-6,8-9,17-19H,1-2H2,(H2,12,13,14)/t5-,6-,8-,9+/m1/s1
|
| InChIKey |
UGRNVLGKAGREKS-GCXDCGAKSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Adenosylhomocysteinase |
Target Info |
Inhibitor |
[2]
|
|---|
| Adenosine A2a receptor |
Target Info |
Inhibitor |
[3]
|
| Adenosine A1 receptor |
Target Info |
Inhibitor |
[3]
|
|
BioCyc Pathway
|
Superpathway of methionine degradation
|
|
Methionine degradation
|
|
Cysteine biosynthesis
|
|
KEGG Pathway
|
Cysteine and methionine metabolism
|
|
Metabolic pathwayshsa04015:Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Vascular smooth muscle contraction
|
|
Parkinson's disease
|
|
Alcoholismhsa04022:cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Morphine addiction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
|
PathWhiz Pathway
|
Selenoamino Acid Metabolism
|
|
Betaine Metabolism
|
|
Methionine MetabolismPW000445:Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Reactome
|
NGF-independant TRKA activation
|
|
Adenosine P1 receptors
|
|
G alpha (s) signalling events
|
|
Surfactant metabolismR-HSA-417973:Adenosine P1 receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Metabolism of amino acids and derivatives
|
|
Trans-sulfuration and one carbon metabolism
|
|
One Carbon Metabolism
|
|
Trans-sulfuration pathway
|
|
Phase II conjugation
|
|
Folate MetabolismWP80:Nucleotide GPCRs
|
|
Monoamine Transport
|
|
GPCRs, Class A Rhodopsin-like
|
|
NGF signalling via TRKA from the plasma membrane
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP80:Nucleotide GPCRs
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007402) |
|---|
| REF 2 | Bioorg Med Chem. 2008 Apr 1;16(7):3809-15. Epub 2008 Jan 30.Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. |
|---|
| REF 3 | J Med Chem. 2000 Jun 1;43(11):2196-203.Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. |
|---|
